SOURCE: SomaLogic


September 23, 2015 10:00 ET

SomaLogic Launches New, Larger Commercial Version of SOMAscan™ Proteomic Assay

"SOMAscan Assay 1.3k" Now Measures 1,310 Protein Analytes in Small Volumes of Multiple Biological Samples, Far Exceeding the Multiplex Capabilities of Any Other Current Technology

BOULDER, CO--(Marketwired - September 23, 2015) - SomaLogic announced today that the latest version of its proprietary SOMAscan proteomics assay, which now measures 1,310 protein analytes, is commercially available to the life science research community. Called "SOMAscan Assay 1.3k," this new version is replacing the current 1,129-measurement version, but without an increase in price.

"We are committed to increasing our already substantial lead in providing sensitive, accurate and highly multiplexed proteomics tools for novel biomarker discovery and development," said Byron Hewett, Chief Executive Officer. "We plan to continue growing the number and diversity of proteins measured in our commercially available SOMAscan assay on a regular basis."

Compared to other current proteomic technologies, SomaLogic's SOMAscan assay offers its research users unprecedented power for novel protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. SOMAscan Assay 1.3k, which incorporates 1,310 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins from high to very low concentrations in small volumes of many different biological sample types.

Many of the nearly 200 new SOMAmer reagents added to the SOMAscan menu target proteins in inflammatory and oncology-related molecular pathways, a particular focus requested by current users of the assay. A list of the 1,310 proteins measured in SOMAscan Assay 1.3k may be downloaded from the SomaLogic website.

SOMAscan Assay 1.3k is primarily available as a service directly from SomaLogic, but access to the assay is also available at a growing number of select biomedical research centers. During the transition to the new SOMAscan version, the 1,129-analyte assay will remain available for a short time at a reduced rate.

To learn more about SOMAscan Assay 1.3k, please visit or contact SomaLogic directly.

About SomaLogic
SomaLogic is transforming healthcare by applying our proprietary protein-measurement technology to the development of new diagnostic tests that deliver a higher quality of life by detecting diseases at their earliest stages and monitoring general wellness. Our ultimate goal is the "Wellness Chip," a single cost-effective and reliable blood test for multiple diseases and conditions that will enable healthcare providers to precisely monitor each individual's state of health and wellness in real time.
Our technology also has multiple potential applications in both life sciences and therapeutics, and it is now available to the entire biomedical scientific community for their own research needs. For more information, visit

Contact Information

  • Editorial Contact

    Fintan R. Steele, Ph.D.
    Executive Director of Corporate Communications
    +1 720-214-3080 - T
    +1 617-816-9834 - M